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Case 1
The patient is a 47-year-old female with a history of coronary
artery disease, hypertension, asthma, diabetes and obstructive
sleep apnea who presented to an outside hospital with shortness
of breath and lethargy. The patient was found to be in diabetic
ketoacidosis, which was treated with an insulin drip. She also
had a platelet count of 8 x 109/L on initial laboratory studies.
She was presumed to have immune thrombocytopenic purpura
(ITP) and treated with five days of intravenous immunoglobulin
(IVIG) without improvement. She was transferred to Thomas
Jefferson University Hospital for further management.
Initial vital signs included a temperature of 100.1 degrees
Fahrenheit, pulse of 101 beats per minute, respiratory rate of
20 breaths per minute, blood pressure of 107/45 mmHg and
oxygen saturation of 100% on room air. On physical exam,
she was lethargic and not oriented. She had pupils that were
equally round and reactive to light; her extraoccular muscles
were intact. She had no lymphadenopathy. Her cardiac exam
revealed a regular rate and rhythm with no murmurs. She
had no crackles in her lung fields. Her abdomen was soft,
non-tender, non-distended, with normal bowel sounds. Her
extremities demonstrated purpuric lesions throughout, but were
non-edematous. Laboratory studies showed a hemoglobin of 6.5
g/dl, white blood cell count of 13.3 x109/L, and platelet count of
65 x109/L. Her creatinine was 0.9 mg/dL.
As there was a concern for thrombotic thrombocytopenic
purpura (TTP), a peripheral blood smear was evaluated and
found to have schistocytes. There was also evidence for microangiopathic hemolytic anemia (MAHA) demonstrated by a lactate
dehydrogenase (LDH) of 1451 IU/L (normal 100-200 IU/L) and
a haptoglobin of 31 mg/dL (normal 16-200 mg/dL). Given the
presence of a low grade fever, MAHA, thrombocytopenia, and
mental status change, a diagnosis of TTP was presumed.
The patient required intubation for airway protection. An
apheresis catheter was placed, and urgent plasmapheresis was
started. Her course was complicated by transient low blood
pressures which were treated with norepinephrine infusion for
two days. Her course was complicated by a spontaneous retroperitoneal hematoma, which accounted for a further decrease in her
hemoglobin and required transfusion of packed red blood cells.
The patient was also treated for a multifocal pneumonia and
clostridium difficile diarrhea. She also had acute renal failure
which was thought to be acute tubular necrosis secondary to her
transient hypotension rather than the TTP.
The patient received 3 weeks of daily plasmapheresis and
high dose intravenous methylprednisolone and then oral
prednisone, with monitoring of her LDH and haptoglobin. She
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also received one dose of rituximab during her hospital stay.
Her ADAMTS13 (an acronym for a disintegrin and metalloproteinase with thrombospondin-1-like domains) activity level was
< 5% (normal more than 67%) and ADAMTS13 inhibitor level
was > 8.0 Inhibitor Units (normal </=0.4 Inhibitor Units). On
discharge, her LDH was 218 IU/L, hemoglobin 10.4 g/dL, and
platelet count 139 x109/L.

Case 2
The patient is a 61-year-old female with a history of systemic
lupus erythematosus, a transient ischemic attack, and human
papilloma virus. Additionally, she had a prior episode of TTP
six years ago that presented with symptoms of confusion and
purpura. She was treated at that time with plasmapheresis. She
presented to an outside hospital with confusion and numbness
of the right neck that radiated down the right arm and leg. The
patient could speak but could not respond appropriately to
questions. She was transferred to Thomas Jefferson University
Hospital for further management.
Initial vital signs included a temperature of 99.3 degrees
Fahrenheit, pulse of 105 beats per min, respiration of 18 breaths
per min, pulse oximetry 98% on room air, and blood pressure
159/85 mmHg. On physical exam, she was alert and oriented to
person, place, and time. She had pupils that were equally round
and reactive to light; her extraocular muscles were intact. She
had no lymphadenopathy. Her cardiac exam had regular rate
and rhythm with no murmurs. She had no crackles in her lung
fields. Her abdomen was soft, non-tender, non-distended, with
normal bowel sounds. Her extremities had no edema, but did
have petechiae on the arms and legs. She had recovered sensation
and strength of her right side. Laboratory studies showed a
hemoglobin of 8 g/dl, white blood cell count of 11.7 x109/L, and
platelet count of 10 x109/L. Her creatinine was 0.9 mg/dL.
A repeat peripheral blood smear confirmed the presence of
schistocytes. Her LDH was 961 IU/L with a haptoglobin of less
than 6 mg/dl, consistent with MAHA. The diagnosis of TTP was
based on her history, as well as low grade fever, mental status
change, thrombocytopenia, and hemolytic anemia.
Plasmapheresis was initiated emergently for a total of six daily
sessions. She was also started on oral prednisone at 80mg
daily, which was tapered after discharge. Her mental status
and laboratory values improved with plasmapheresis. Her
ADAMTS13 activity level was <5 % (normal more than 67%)
and ADAMTS13 inhibitor level was <0.4 Inhibitor Units
(normal </= 0.4 Inhibitor Units). On the day of discharge, the
patient’s LDH was 174 IU/L, haptoglobin 264 mg/dl, hemoglobin
11.2 g/dL, and platelet count 508 x109/L. One month after
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discharge, ADAMTS13 activity level had risen to 34%, while the
ADAMTS13 inhibitor level continued to be <0.4 Inhibitor Units.
The hematologist consulted on this case believed that the patient
had a congenital form of TTP demonstrated by an overlap
syndrome with low activity levels in the absence of inhibitors.

Discussion
Thrombotic thrombocytopenic purpura (TTP) is a rare
condition on the spectrum of disorders termed thrombotic
microangiopathies (TMA). It is characterized by the presence
of acquired microangiopathic hemolytic anemia (MAHA),
thrombocytopenia, fluctuating neurological symptoms, renal
dysfunction and fever.1 TTP can be seen at any age though
predominately it presents in the 4th decade of life. It is estimated
that the annual incidence of TTP in the United States is 4 to 11
cases per a million individuals. Additionally, the incidence of
TTP in women is greater than men by approximately 2 to 2.5
times, and black to non-blacks at approximately 3 to 5 times
greater.2 Though typical of TTP, the constellation of findings
that constitute the classical pentad can also be seen in other
TMAs. These include hemolytic uremic syndrome or MAHA
associated with other causes including metastatic cancer, organ
transplantation, and connective tissue diseases.3 Furthermore,
not all features of the pentad need be present to diagnose
TTP. Treatment initiation, particularly plasma exchange, can
significantly decrease the mortality of the disorder and is often
initiated prior to confirming the diagnosis. The purpose of this
paper is to raise the index of suspicion for a diagnosis of TTP in
cases of thrombocytopenia and to expedite prompt implementation of effective therapy.

Categories of TTP
TTP can be classified into subcategories, namely idiopathic TTP
and familial TTP. Idiopathic TTP is the predominant form of
TTP. It can be further subdivided into acute TTP (occurring
without a known precipitant and once treated typically resolves
within 4 weeks and without relapses), and relapsing TTP
(wherein episodes of TTP respond to therapy with relapses
occurring as early as 4 weeks after therapy). Familial TTP carries
a poor prognosis and is usually transmitted via an autosomal
recessive pattern of inheritance.1

Pathophysiology
The hallmark feature of TTP is the presence of microvascular
thrombi in arterioles and capillaries throughout the body.
These microvascular thrombi consist of platelets with a small
amount of fibrin surrounded by proliferative endothelial cells.
This contrasts to the typical thrombi noted in HUS which
are composed of mostly fibrin with few platelets. In addition,
TTP thrombi are more disseminated than those of HUS, and

are found in the heart, pancreas, kidneys, adrenal glands and
brain. Conversely, HUS thrombi typically affects the kidneys
predominantly. 4 Other organs including the lungs, skeletal
muscles, liver and gastrointestinal tract may be affected by
TTP thrombi albeit to a lesser extent and may contribute to the
constellation of symptoms that an individual patient may express.
The hemolytic anemia seen in TTP results from alterations in
microcirculation, in addition to the passage of red blood cells
through partially occluded vessels. The peripheral destruction
of platelets and their aggregation into microthrombi, as well as
disruption of circulating red blood cells, leads to the presence
of schistocytes and the paucity of platelets characteristic of the
blood smear in TTP.

Von Willebrand factor and ADAMTS13
Von Willebrand factor (vWF) is found in the platelet rich
thrombi of TTP patients. It is a large, multimeric plasma
glycoprotein that mediates platelet adhesion and subsequent
thrombus formation at areas of vascular damage. It is synthesized
in the endothelium and megakaryocytes and secreted into
plasma as large multimers or “strings”. These multimers are
subsequently cleaved by a metalloproteinase enzyme to prevent
their entrance into or persistence in plasma. This metalloproteinase is called ADAMTS13. Once cleaved, the adhesion of
platelets to monomers of vWF does not occur in the absence of
vascular damage. In patients with a deficiency of ADAMTS13
or impaired activity of this enzyme, these large multimers of
vWF are not cleaved. In this form, they may act as the nidus
for platelet aggregation and subsequent thrombi formation. In
patients with familial thrombotic thrombocytopenic purpura,
unusually large multimers of vWF can be found in the plasma.
Their plasma ADAMTS 13 activity is undetectable to barely
detectable. For patients with idiopathic TTP, plasma levels
of ADAMTS 13 are barely detectable during the episode but
normalize following recovery.5
Remuzzi et al. showed that during the acute phase of TTP a
complete deficiency of ADAMTS13 activity had a sensitivity of
92% and a specificity of 44%. For patients in remission, complete
deficiency of ADAMTS13 activity had a sensitivity of 41% and
a specificity of 82% for diagnosis of TTP. In patients with
antibodies against ADAMTS13, the specificity of diagnosing
TTP was 100%.7 Further studies have shown that survivors of
an acute episode of acquired TTP with severely reduced levels
of ADAMTS13 or with anti-ADAMTS13 antibodies during
remission have an approximately three-fold greater likelihood
of developing another episode of TTP than patients with higher
protease activity and no antibody.6
Whether ADAMTS13 deficiency is the sole cause of TTP is
uncertain. Studies evaluating the role of ADAMTS13 deficiency
in the presence of multimeric vWF imply that other factors may
play a role in the pathogenesis of TTP.7
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Risk Factors

Renal failure

Apart from an inherited or acquired deficiency of ADAMTS13,
other factors have been shown to be related to TTP exacerbations
or acute episodes. These include pregnancy, HIV infection,
and obesity.3 In addition, the use of several medications has
been associated with TTP. These include antiplatelet agents
(ticlopidine, clopidogrel), antineoplastic agents (mitomycin,
cyclosporine and quinine), cocaine, as well as other drugs
including antibiotics and statins.8

Renal involvement is a predominant feature in HUS, but found
in variable degrees in TTP. Proteinuria and hematuria are the
cardinal features.10 Elevations of creatinine and serum BUN
are milder on average when compared to HUS cases. However,
acute severe TTP cases may present with a higher degree of
renal involvement compared to mild or relapsing cases. For
these patients, markedly elevated serum BUN on admission
may indicate a poor prognosis.11

Clinical/Laboratory Manifestations

Other Manifestations

Of the classic pentad, hemolytic anemia, thrombocytopenia,
and neurologic symptoms are most frequently identified and
are found in 74% of patients. Conversely, fever and renal
involvement are identified in 40% of patients.3 The multitude of
organ systems involved leads to varied symptomatology.

Hematologic
Thrombocytopenia

Gastrointestinal. Microthrombotic lesions throughout the
gastrointestinal tract can result in varying abdominal symptoms;
abdominal pain is seen in 11 to 15% of patients. Pancreatitis is
also seen as a result of TTP episodes.3

Treatment

Platelet counts on average can be 25 x109/L, with approximately
55% of patients having a platelet count of less than 20 x109/L.
Peripheral platelet destruction or utilization can be the cause of
thrombocytopenia.1 Low platelets lead to the purpuric lesions,
gingival bleeding, retinal hemorrhages, mucosal bleeding, and
petechial hemorrhages.

The mortality of TTP surpassed 90% prior to the use of plasma
therapy. 17 A recent study from Johns Hopkins University
revealed as high as a 91% survival benefit when prompt initiation
of treatment could be achieved.12 Additional findings in patients
with severe TTP episodes showed that 83% of patients (20 of 24
patients with creatinine ranging from 1.4 to 10.8 mg/dl) had
improvement of disease when treated with plasma exchange.13

Hemolytic anemia

Mainstay of Therapy

Hemoglobin levels are usually greater than 10 g/dL, revealing
a moderate anemia. Hemolytic anemia is suggested by a
negative direct antiglobulin test (Coomb’s test). Other findings
of hemolytic anemia include increased reticulocytes, LDH,
indirect bilirubinemia, and decreased or absent haptoglobin
levels. In addition, schistocytes on the peripheral blood smear
are characteristic in patients with TTP. Presence of schistocytes
in the peripheral blood of TTP patients varies from 0% to 18%
of red blood cells.3

Neurologic
Neurologic findings are the most common symptom and
are identified in up to 75% of TTP cases. These can include
confusion, headache, altered mental status, focal loss of motor
or sensory functions, convulsions, stupor, and coma. Typically,
neurological symptoms are transient and attributed to formation
and dissolution of microthrombi in cerebral circulation. Because
of their fleeting nature, the effects of TTP thrombi on cerebral
circulation may be misdiagnosed as transient ischemic attacks.3
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Fever, though a part of the pentad, is not frequently found in
TTP episodes. High fevers should alert the clinician of a possible
infectious etiology.8

Plasma exchange (PE) is the main treatment modality for
TTP. Several studies propose its superiority to other modalities
including plasma infusion (PI). 14 The theory behind the use
of plasma exchange lies in the removal of auto-antibodies
against the ADAMTS13 as well as the large vW multimers,
while simultaneously supplying missing or deficient plasma
constituents, such as the metalloproteinase ADAMTS13.
PE should be instituted within 24 hours of presentation,
particularly in severely affected patients. If PE is not available,
patients should be bridged by PI (at least 25 ml/kg per day).15
Optimal dosing of plasma exchange is still unknown. Single
volume PE, in which patients receive a plasma volume that is
the same as their predicted plasma volume, can be initiated
at presentation. More intensive exchange regimens can be
used in cases of resistant TTP by either increasing PE volumes
to 1.5 times the predicted patient’s plasma volume or by
performing twice daily PE of 1-1.5 plasma volumes. Daily
PE should be continued until 2 days after remission; usually
defined as normalization of neurological status, normal platelet
count (> 150 x109/L), normal LDH values, and an increasing
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hemoglobin.15 Adverse events associated with plasma exchange
include systemic infections, allergies or anaphylactoid reactions,
pneumothoraces, hemorrhages, catheter associated thrombi,
hypoxemia, hypotension, and serum sickness.16

Ancillary Therapy
Glucocorticoid therapy has been shown to improve mild cases of
TTP.14 Steroids are also used frequently during plasma exchange.
Antiplatelet agents have shown no therapeutic advantage over
plasma exchange. In addition, the use of antiplatelet agents may
be associated with an increased bleeding risk; as a result, their
use has largely fallen out of favor.14,15
Though plasma exchange is still the preferred treatment
modality for acute and relapsing cases of TTP, there exists a
subgroup of patients with impaired response to this therapy.
For such patients, other modalities may provide some benefit.
The use of vincristine in TTP predated that of plasma exchange.
Recent studies indicate that its use may have therapeutic benefit
in patients who are refractory to plasma exchange.19 Likewise,
rituximab has also been shown to be helpful in patients who
do not respond to plasma exchange therapy, particularly if a
persistent inhibitor is noted.17 Splenectomy is also used in the
management of TTP. Some studies report no therapeutic benefit
during the acute episode.14 However, others have claimed that
when performed in remission, splenectomy leads to a decrease in
the recurrence rate of TTP in patients with a history of relapse. 18

Summary
TTP is a rare condition, but one that carries a high mortality.
Symptoms result from microthrombi affecting microcirculation
and can be varied depending on the organs involved. The astute
clinician must have a high index of suspicion for TTP in any
patient presenting with hemolytic anemia and thrombocytopenia, particularly with concomitant fluctuating neurologic
dysfunction. Not all characteristics of the classic pentad need to
be present to raise suspicion or initiate therapy. The mainstay of
therapy is plasma exchange, which may be used in conjunction
with steroids. If plasma exchange is not readily available,
plasma infusion can be initiated until plasma exchange is
started. Other modalities that may provide therapeutic benefit
in cases of relapsing TTP or in patients with slow or partial
response to plasma exchange include vincristine and rituximab.
Splenectomy done in remission may decrease recurrence in
patients with relapsing TTP.
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